Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

TRADING UPDATE

7 Apr 2010 07:00

RNS Number : 7878J
ViaLogy PLC
07 April 2010
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

TRADING UPDATE

 

London, April 7, 2010. ViaLogy (LSE: VIY). The board of ViaLogy announces that the fiscal year ending March 31, 2010, marks a year of strong performance highlighted by the successful introduction of QuantumRD seismic analysis and reservoir characterization technology to the hydrocarbon energy market. ViaLogy ends the year with 12 clients under contract, including two key industry independent E&P firms, and a strong sales pipeline which should produce additional high quality Exploration and Production company customers in the coming months. The five successfully completed wells have demonstrated the ability of QuantumRD to locate productive hydrocarbon deposits in a variety of formations.ViaLogy's strategy going forward is to work closely with clients to exercise the technology in as yet untried areas of major significance, especially to bring QuantumRD to shale gas and offshore exploration plays. ViaLogy's work for contracted clients has produced an inventory contingent backlog of over 60 probable future wells to be drilled at locations recommended by ViaLogy. The Company stresses that the ultimate decision to drill, drilling schedules, and locations are dependent upon clients' operational plans, as are business decisions about the timing of hydrocarbon extraction.

The five successful well completions have been at widely separated locations in Texas ranging from 3,000 ft to 12,000 ft in depth. These targeted structural and stratigraphic formations include carbonates, vugs, clastic sediments and channel sands. The deliverables provided analysis of formation porosity, lithology and fluid presence.

ViaLogy'stechnical staff now includes experienced and industry geophysical specialists, and two to three more will join the staff in the coming months. In addition, ViaLogy will establish a Houston office to accelerate business development objectives and maintain close access to the customer base.

ViaLogy has ambitious objectives for the coming year. The focus will be on additional strong customers and repeat business, further establishing the Company's business model where payment is received through substantial up-front service fees and a share of income from successful wells. It should be emphasized that while QuantumRD - based on proprietary active signal processing technology that uniquely exploits signal spectrum and associated noise to extract more, and more precise, information from seismic data - will not prove successful in 100 per cent. of cases, it should significantly de-risk exploration as compared with current industry methods.

The coming months should see drilling of four to five new ViaLogy-positioned wells, some with new and some with established clients, and that number will increase over the course of the coming year. In its latest project, San Antonio-based client Atascosa is currently determining whether to do a deviated drilling completion of its Escondido well or to drill at another nearby ViaLogy designated location. Initial results indicate that the drilling process may have failed to achieve the placement accuracies set by ViaLogy, but has confirmed that QuantumRD analysis accurately located a pay zone and determined porosity. It is always up to the operator to determine if the expense of well completion is justified by the operator-estimated amount of profitably extractable oil, i.e. the standard he sets for his own operating margins. Atascosa's other two producing wells will be reworked in the coming months to bring them up to optimal production; such rework is typical and may include installation of larger pump and cement squeeze into the formations.

CEO Robert Dean said, "I'm very pleased that we've been able to achieve as much as we have during the last year. Anyone with experience will tell you unabashedly that you have to prove yourself to win acceptance in the oil industry, and that it doesn't come easily. Also, it's not academic - it's about finding oil. ViaLogy has done this in very challenging situations. We have successfully completed a significant number of QuantumRD wells, and, very significantly, our retrospective analysis showed why previous drilling efforts had produced dry holes for over 20 wells. The technology's ability to accurately and repeatably predict the presence of hydrocarbons and to estimate porosity are two of the critical variables in the high-risk exploration world. We are building our team of industry professionals and we can now look forward to a major year that brings ViaLogy to another level of industry acceptance for our pathbreaking QuantumRD."

 

For further information please contact:

 

ViaLogy plc

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Jeremy Stephenson / Katie Ratner, Corporate Broking +44 (0) 20-7107-8000

 

 

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com. Except for statements of historical fact, the information presented herein constitutes forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQQLFBBZFXBBZ
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.